Critical Actions in Emergency Medicine: Timely Diagnosis and Treatment of CAR-T and Bispecific Antibody–Related AEs in Multiple Myeloma

Review strategies for emergency medicine team screening and management of patients with multiple myeloma receiving CAR T-cell therapy or bispecific antibodies who present to the emergency department for care. Review a downloadable slideset, a CME/CE-certified on-demand webcast, and an expert commentary.

Share

Program Content

Activities

CAR T and Bispecific AEs in MM
Critical Actions in Emergency Medicine: Timely Diagnosis and Treatment of CAR T-Cell‒ and Bispecific Antibody‒Related AEs in Multiple Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 19, 2024

Activities

AEs in MM
Critical Actions in Emergency Medicine: Timely Diagnosis and Treatment of CAR-T and Bispecific Antibody–Related AEs in Multiple Myeloma
Video
Congratulations: You achieved a completion on 04/09/2022

Released: March 01, 2024

Expires: February 28, 2025

Faculty

cover img faculity

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Chief, Hematology
Co-Director, Myeloma Program
University of California,
San Francisco Medical Center
San Francisco, California

cover img faculity

Shonali Midha, MD

Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Instructor, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Noopur Raje, MD

Director
Center for Multiple Myeloma
Rita Kelly Chair in Oncology
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC